非移植用脐带血单位作为白血病过继免疫治疗来源及医学循环经济范式
本研究探索利用不符合异基因造血干细胞移植资格的脐带血单位(UCBU),在优化培养条件下临床规模生产CD34+细胞来源的髓系树突状细胞(DC),进而生成针对WT1和PRAME的双价白血病特异性T细胞(Leuk-ST)。该双价Leuk-ST包含以效应记忆表型为主的CD8+和CD4+ T细胞亚群,对WT1和PRAME均表现出高特异性和细胞毒性。研究提供了循环经济范式及未来Leuk-ST库作为第三方现成T细胞产品治疗急性白血病的平台。
要点
- 非移植用UCBU可重复性生产临床规模CD34+来源髓系DC和双价Leuk-ST。
- 双价Leuk-ST以效应记忆表型为主,对WT1和PRAME具高特异性和细胞毒性。
- 提出UCBU再利用的循环经济范式及现成T细胞产品库平台。
核心结论
- 利用非移植用UCBU可临床规模生成靶向WT1和PRAME的双价Leuk-ST,为急性白血病提供第三方现成T细胞产品平台。
研究设计与样本
- 研究利用不符合异基因造血干细胞移植资格的脐带血单位(UCBU),优化培养条件生成CD34+细胞来源髓系DC和双价Leuk-ST。
主要发现
- 可重复性临床规模生产CD34+细胞来源髓系DC及后续多克隆双价Leuk-ST。
- 双价Leuk-ST含以效应记忆表型为主的CD8+和CD4+ T细胞亚群。
- 双价Leuk-ST对WT1和PRAME均表现高特异性和细胞毒性。
临床怎么用
- 非移植用UCBU可被再利用作为Leuk-ST生产来源,支持未来建立第三方现成T细胞产品库。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in immunotherapy with T cells armed with chimeric antigen receptors (CAR-Ts), opened up new horizons for the treatment of B-cell lymphoid malignancies. However, the lack of appropriate targetable antigens on the malignant myeloid cell deprives patients with refractory acute myeloid leukaemia of effective CAR-T therapies. Although non-engineered T cells targeting multiple leukaemia-associated antigens [i.e. leukaemia-specific T cells (Leuk-STs)] represent an alternative approach, the prerequisite challenge to obtain high numbers of dendritic cells (DCs) for large-scale Leuk-ST generation, limits their clinical implementation. We explored the feasibility of generating bivalent-Leuk-STs directed against Wilms tumour 1 (WT1) and preferentially expressed antigen in melanoma (PRAME) from umbilical cord blood units (UCBUs) disqualified for allogeneic haematopoietic stem cell transplantation. By repurposing non-transplantable UCBUs and optimising culture conditions, we consistently produced at clinical scale, both cluster of differentiation (CD)34+ cell-derived myeloid DCs and subsequently polyclonal bivalent-Leuk-STs. Those bivalent-Leuk-STs contained CD8+ and CD4+ T cell subsets predominantly of effector memory phenotype and presented high specificity and cytotoxicity against both WT1 and PRAME. In the present study, we provide a paradigm of circular economy by repurposing unusable UCBUs and a platform for future banking of Leuk-STs, as a 'third-party', 'off-the-shelf' T-cell product for the treatment of acute leukaemias.
引用
- Koukoulias K, Papadopoulou A, Kouimtzidis A, et al. Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine. Br J Haematol. 2021. PMID: 34036576. doi:10.1111/bjh.17464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。